Exelixis (EXEL) Competitors $39.15 +0.08 (+0.20%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$39.35 +0.20 (+0.51%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. BIIB, UTHR, INCY, NBIX, BMRN, EXAS, IONS, MDGL, HALO, and RGENShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exelixis vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Ionis Pharmaceuticals Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends. Do insiders and institutionals have more ownership in EXEL or BIIB? 85.3% of Exelixis shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.8% of Exelixis shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, EXEL or BIIB? Exelixis has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Do analysts rate EXEL or BIIB? Exelixis presently has a consensus target price of $44.06, suggesting a potential upside of 12.53%. Biogen has a consensus target price of $181.65, suggesting a potential upside of 25.40%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exelixis 1 Sell rating(s) 9 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.52Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32 Does the media refer more to EXEL or BIIB? In the previous week, Exelixis had 4 more articles in the media than Biogen. MarketBeat recorded 25 mentions for Exelixis and 21 mentions for Biogen. Biogen's average media sentiment score of 1.33 beat Exelixis' score of 1.21 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 16 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 14 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, EXEL or BIIB? Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExelixis$2.23B4.73$521.27M$2.0818.82Biogen$9.68B2.20$1.63B$10.4613.85 Is EXEL or BIIB more profitable? Exelixis has a net margin of 27.01% compared to Biogen's net margin of 15.31%. Exelixis' return on equity of 27.47% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Exelixis27.01% 27.47% 20.88% Biogen 15.31%13.85%8.32% SummaryExelixis beats Biogen on 10 of the 16 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.52B$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio18.8221.4375.4125.98Price / Sales4.73432.54515.86180.60Price / Cash20.2846.6837.5660.44Price / Book4.989.6112.156.29Net Income$521.27M-$53.29M$3.29B$271.07M7 Day Performance3.35%0.13%0.74%3.87%1 Month Performance1.77%5.55%5.00%5.49%1 Year Performance47.96%10.44%62.55%25.86% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.6945 of 5 stars$39.15+0.2%$44.06+12.5%+48.0%$10.52B$2.23B18.821,147Positive NewsBIIBBiogen4.6966 of 5 stars$142.50+0.8%$181.65+27.5%-26.0%$20.89B$10.00B13.627,605Positive NewsUTHRUnited Therapeutics4.7826 of 5 stars$397.89+0.8%$429.62+8.0%+19.4%$17.90B$3.08B15.491,305Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionINCYIncyte4.7498 of 5 stars$85.83-0.8%$82.53-3.8%+30.7%$16.76B$4.24B19.502,617Positive NewsAnalyst DowngradeShort Interest ↓NBIXNeurocrine Biosciences4.7533 of 5 stars$143.03-0.5%$160.00+11.9%+16.0%$14.18B$2.36B42.311,800News CoveragePositive NewsBMRNBioMarin Pharmaceutical4.9644 of 5 stars$55.57-1.4%$92.04+65.6%-36.3%$10.67B$2.85B16.493,040Analyst UpgradeShort Interest ↑EXASExact Sciences4.7917 of 5 stars$55.04+2.1%$67.05+21.8%-17.7%$10.42B$2.76B-10.137,000Trending NewsAnalyst ForecastShort Interest ↓Analyst RevisionIONSIonis Pharmaceuticals3.6628 of 5 stars$64.06+5.0%$67.88+6.0%+49.7%$10.21B$944.05M-34.821,069Insider TradeMDGLMadrigal Pharmaceuticals4.2048 of 5 stars$443.25-2.3%$471.13+6.3%+78.8%$9.84B$180.13M-34.4990Analyst ForecastInsider TradeHALOHalozyme Therapeutics4.5701 of 5 stars$75.86+0.0%$67.11-11.5%+23.4%$8.86B$1.18B17.34390Positive NewsInsider TradeRGENRepligen4.8477 of 5 stars$118.66-1.7%$169.55+42.9%-18.9%$6.65B$673.96M-472.621,778Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Ionis Pharmaceuticals Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EXEL Stock Alerts